Mid-October 2026 concentrates several announcements that directly impact medical practice and public health in France. Winter vaccination campaign, drug shortages, unit sales in pharmacies, work of the High Authority of Health: the topics of this week outline the contours of a healthcare system in full adaptation.
Surveillance of arboviruses in mainland France: where do we stand in October 2026
The enhanced surveillance of arboviruses (dengue, chikungunya, Zika, West Nile) continues in metropolitan France under the coordination of Public Health France. The bulletin published on October 7 covers the summer and autumn period, during which the tiger mosquito remains active in several departments in the south and along the Atlantic coast.
This seasonal system allows for the detection of imported cases before local transmission establishes itself. Each report triggers an entomological investigation and, if necessary, targeted mosquito control operations. The Oscour network, which aggregates emergency room visits, complements this framework by detecting unusual signals of fever or flu-like syndrome outside the flu season.
The issue is not theoretical: indigenous cases of dengue have been documented in recent years in the south of France. The real-time monitoring of this data, accessible on all pages of France Médicale as well as on the bulletins from Public Health France, remains the primary lever to limit the spread.
Flu and Covid-19 vaccination campaign: launch on October 13
The national vaccination campaign against the flu began on October 13. As every autumn, it primarily targets people over 65, pregnant women, patients with chronic diseases, and healthcare professionals.
The novelty of this season lies in the parallel recommendation for Covid-19 vaccination for at-risk populations. The two injections can be administered on the same day, in different arms, simplifying the vaccination process.
Prevention of bronchiolitis in infants
For lower respiratory infections in infants, two strategies now coexist. The first is vaccination of the mother during pregnancy, which transfers protective antibodies to the fetus. The second relies on the direct immunization of the newborn with a monoclonal antibody administered before the epidemic season.
The choice between these two approaches depends on the timing of the pregnancy and the birth period. A child born in early autumn will benefit more from the monoclonal antibody, while maternal vaccination in the third trimester protects a child born in mid-winter. The treating physician or midwife guides families accordingly.
Drug shortages: a national experiment in pharmacies
The supply tensions in medications have been a recurring problem for several years. Health authorities are currently testing a new early detection system for shortages, directly involving community pharmacies.
The mechanism targets medications of major therapeutic interest (MITM), meaning those whose unavailability can jeopardize life or lead to a loss of opportunity for the patient.
- The experiment is not yet a permanent national system: it aims to validate the reliability of information reported from pharmacies.
- Participating pharmacists report in real-time the shortages observed, allowing authorities to anticipate prescription delays.
- If successful, the system could be generalized across the territory and integrated into the continuous monitoring of the ANSM.
Unit sale of medications: an expansion under discussion in Parliament
An amendment adopted in the Social Affairs Committee as part of the Social Security Financing Bill (PLFSS) for 2027 proposes to expand unit sales beyond antibiotics. Previously limited to a few specialties, this practice could involve more therapeutic classes.
The stated objective is twofold: to reduce waste of unused medications and to limit self-medication from opened boxes. In practice, the measure raises several technical questions.
- Unit repackaging requires compliant labeling, with lot number and expiration date legible on each tablet or packet dispensed.
- Pharmaceutical traceability must be maintained at every step, from wholesaler to patient.
- The remuneration of pharmacists for this additional service remains to be defined in the final text.
The amendment still has to pass several stages of the parliamentary process. Its final adoption is therefore not guaranteed at this stage.
Work of the HAS: artificial intelligence and re-evaluation of treatments
The High Authority of Health is preparing several opinions that could modify care practices in the coming months. Among the announced files are the evaluation of the role of artificial intelligence in care pathways, as well as a re-evaluation of older medications whose therapeutic place has evolved since the arrival of innovative molecules.
An opinion on anti-CGRP treatments for migraines is also expected. These monoclonal antibodies, which target the calcitonin gene-related peptide, represent an advancement for patients suffering from chronic migraines resistant to conventional treatments. The HAS’s re-evaluation will determine their reimbursement conditions and their positioning in the therapeutic strategy.
These works illustrate a fundamental trend: the HAS is increasingly intervening early in the life cycle of innovations, even before their wide dissemination, to frame their use and ensure an acceptable benefit-cost ratio for Health Insurance.
The week of October 13, 2026, reminds us that French medical news is not limited to major announcements. Behind every decision from the ANSM, every amendment of the PLFSS, or every epidemiological bulletin, there are concrete decisions that affect the availability of treatments and the quality of prevention on the ground.
